Affiliation:
1. Kemerovo State University;
St. Luke's Clinical Hospital
2. Kemerovo State Medical University
3. St. Luke's Clinical Hospital
4. Kemerovo State Medical University;
Kuzbass Clinical Emergency Hospital named after M. A. Podgorbunsky
Abstract
Purpose of the study. To evaluate the levels of metabolic markers in patients with prostate cancer (PCa) in comparison with patients with benign prostatic hyperplasia (BPH).Patients and methods. 108 patients were included in the study. The majority of patients had comorbidities: coronary heart disease, hypertension, and almost one third of patients had type 2 diabetes mellitus. Median (Me) age was 67 (64–74), body mass index was 25.9–34.7. The main study group included 54 patients with histologically verified prostate cancer, the comparison group consisted of 54 patients with benign prostatic hyperplasia (BPH). The level of basic biochemical parameters, glomerular filtration rate, lipidogram, total prostate-specific antigen (PSA), total testosterone was determined in all patients.Results. When comparing anamnestic and biochemical parameters, the groups were not statistically significantly different. When comparing the groups by lipid status, it turned out that in the group with RPW, in contrast to the group of patients with BHP, statistically significantly higher levels of total cholesterol (5.13 (3.3–10,4) and 4.60 (2.5–6.3)) mmol/L, respectively, p = 0.023), low–density lipoproteins (2.93 (0.8–5.9) and 2.60 (0.9–4.2) mmol/L, respectively, p = 0.035), triglycerides (2.10 (1.0–8.0) and 1.70 (0.5–7.3) mmol/L, respectively, p = 0.048). In case of dyslipidemia, an increased risk of developing PCa was identified. Correlation analysis revealed a direct moderate relationship between total PSA levels and total cholesterol concentration (r = 0.51).Conclusion. Our study revealed that in the PCa group, there was a higher level of total cholesterol, low-density lipoproteins, and triglycerides, in contrast to the group of patients with BPH. Additionally, in the group of patients with BPH, dyslipidemia was a risk factor in the development of PCa, which should be taken into account in PCa prevention and diagnosis.
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference24 articles.
1. Hryniewicz-Jankowska A, Augoff K, Sikorski AF. The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer. Exp Biol Med (Maywood). 2019 Oct;244(13):1053–1061. https://doi.org/10.1177/1535370219870771
2. Kaprin AD, Alekseev BIa, Matveev VB, Pushkar’ DIu, Govorov AV, Gorban’ NA, et al. Prostate cancer. Clinical recommendations. Journal of Modern Oncology. 2021;23(2):211–247. (In Russ.). https://doi.org/10.26442/18151434.2021.2.200959
3. Toivanen R, Shen MM. Prostate organogenesis: tissue inducti , hormonal regulati and cell type specifi ati . Development. 2017 Apr 15;144(8):1382–1398. https://doi.org/10.1242/dev.148270
4. Shatylko TV, Popkov VM, Korolev AYu, Fomkin RN, Krylova OV. Role of androgen receptors in pathogenesis of prostate cancer. Oncology Bulletin of the Volga region. 2018;2:18–23. (In Russ.).
5. Ryabova VM, Voskresenskiy MA, Popova BV. Role of the Tumor Suppressor RB in Development of Localized and Castration-Resistant Prostate Cancer. Cell and Tissue Biology. 2022;64(3):208–215. (In Russ.).